CLDN18.2-positive Gastric Adenocarcinoma
1 competing product in clinical development for CLDN18.2-positive Gastric Adenocarcinoma.
Pipeline by Phase
Phase 11
All Products (1)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| IMAB362 + Zoledronic acid + Interleukin-2 (1 million IU) + Interleukin-2 (3 million IU) | Astellas Pharma | Phase 1 | Completed | 29 |